Mike Matson

Although Boston Scientific Corp (NYSE:BSX) reported fourth-quarter revenue and earnings ahead of consensus estimates, it announced disappointing 2026 guidance, according to Needham. The Boston Scientific Analyst: Analyst Mike Matson maintained a Buy rating, but slashed the price target from $121 to...

Shares of Medtronic PLC (NYSE:MDT) inched higher in early trading on Wednesday, as the company on Tuesday reported strong fiscal second-quarter results. MDT is approaching key resistance levels. Follow the breaking news here. Here are some key analyst takeaways: Needham analyst Mike Matson...

According to Needham, Lucid Diagnostics Inc. (NASDAQ:LUCD) is likely to receive approval for EsoGuard testing-related Medicare reimbursement, which would boost testing volumes. The Lucid Diagnostics Analyst: Analyst Mike Matson maintained a Buy rating and price target of $3. The Lucid Diagnostics...

Wright Medical Group NV (NASDAQ: WMGI)'s acquisition of Cartiva, a private orthopedic medical device company, resulted in a pullback in the stock that investors should take advantage of, according to Needham. The Analyst Needham's Mike Matson upgraded Wright Medical Group from...

Inogen Inc (NASDAQ: INGN) dropped more than $10 per share Thursday morning as a pair of analysts butted heads over the stock. Citron Research’s Andrew Left published a new report on Inogen in which he said Inogen is facing the prospect of stiff competition and doing so with undifferentiated...

Shares of medical device maker Boston Scientific Corporation (NYSE: BSX) received a top-notch rating Friday from Needham. The Analyst Needham analyst Mike Matson upgraded shares of Boston Scientific from Buy to Strong Buy with a $32 price target. The Thesis First, Boston Scientific...